文献速递白血病造血干细胞移植与细胞治疗

高亲和力人源化抗CD19 CAR-T细胞的构建及体外验证

[Construction and in vitro verification of a new humanized anti-CD19 CAR-T cells with high affinity].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

研究构建了基于鼠源FMC63抗体人源化改造的高亲和力抗CD19 CAR-T细胞(hCART19),在Raji和CHO-K1-CD19靶细胞中验证其体外杀伤与细胞因子分泌能力,并在白血病小鼠模型中观察到hCART19组存活时间>40天,为后续临床研究奠定基础。

要点

  • 获得与FMC63结合能力相似的人源化CD19抗体克隆H3L2并构建hCART19。
  • 效靶比10∶1时hCART19对Raji细胞杀伤率(87.56±1.99)%,高于两对照组(P<0.001)。
  • 白血病小鼠模型中hCART19组存活>40天,两对照组20~30天全部死亡(P=0.008)。

核心结论

  • 成功构建了具有抗白血病活性的人源化CD19 CAR-T细胞,为下一步临床研究奠定了基础。

研究设计与样本

  • 研究将鼠源抗人CD19抗体FMC63进行人源化改造,构建携带人源化CD19 CAR序列的慢病毒载体并转染人外周血CD3(+) T细胞获得hCART19。
  • 体外采用LDH释放实验和ELISA检测杀伤与细胞因子分泌,靶细胞为Raji及CHO-K1-CD19,效应细胞设hCART19组、未转染T细胞阴性组和对照病毒转染T细胞对照组。
  • 体内采用人白血病异种移植小鼠模型,尾静脉分别注射hCART19、对照病毒转染T细胞及未转染T细胞,观察存活时间。

主要发现

  • LDH释放实验显示随效靶比增加靶细胞杀伤率逐渐增加,效靶比10∶1时hCART19组杀伤率最大。
  • 以Raji为靶细胞时hCART19组杀伤率(87.56±1.99)%高于阴性组(19.31±1.16)%及对照组(21.35±1.19)%(P值均<0.001)。
  • 以Raji为靶细胞时hCART19组IL-2(10.56±0.88)pg/ml及IFN-γ(199.02±12.66)pg/ml较阴性组[IL-2(3.55±0.26)pg/ml;IFN-γ(37.63±0.85)pg/ml]及对照组[IL-2(2.92±0.32)pg/ml;IFN-γ(52.07±3.33)pg/ml]明显升高(P值均<0.001)。
  • 以CHO-K1-CD19为靶细胞时上述实验出现相似结果。
  • 白血病小鼠模型中hCART19组存活时间>40 d,阴性组和对照组小鼠在20~30 d全部死亡,差异有统计学意义(χ(2)=11.73,P=0.008)。

临床怎么用

  • 原文结论为成功构建了具有抗白血病活性的人源化CD19 CAR-T细胞,为下一步临床研究奠定了基础。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To construct humanized anti-CD19 chimeric antigen receptor T cells and investigate its ability to kill leukemia cells in vitro and in vivo. Methods: Humanized anti-human CD19 antibody with a high affinity was obtained based on mouse anti-human CD19 antibody (FMC63). Humanized CD19 CAR-T cells (hCART19) were constructed through transfection of lentivirus carrying a CAR sequence of humanized anti-CD19 scFv into human peripheral CD3(+) T cells. The ability of hCART19 to kill leukemia cells and secrete cytokines was detected by LDH release assay and ELISA. The in vivo tumor-killing effect of hCART19 was evaluated in a leukemia mouse model. Results: Several different humanized CD19 single-chain antibodies which were constructed by IMGT database were expressed in the eukaryotic expression vector and purified followed by acquiring humanized CD19 antibody (Clone H3L2) with similar binding ability to FMC63. Humanized CD19 CAR lentivirus vector was constructed and transfected into T cells to obtain hCART19 cells. The LDH release experiment confirmed that the killing rate of target cells was increased gradually along with the increased E/T ratio. When the ratio of E/T was 10∶1, the killing rate of target cells by hCART19 reached a maximum. When Raji cells were used as target cells, the hCART19 cells group had a significantly higher kill rate [(87.56±1.99)%] than the untransduced T cells group [(19.31±1.16)%] and the control virus transduced T cells group [(21.35±1.19)%](P<0.001). ELISA analysis showed that the secretion of IL-2 [ (10.56±0.88) pg/ml] and IFN-γ [ (199.02±12.66) pg/ml] in the hCART19 cells group were significantly higher than those in the untransduced T cells group [IL-2: (3.55±0.26) pg/ml; IFN-γ: (37.63±0.85) pg/ml] and the control virus transduced T cells group [IL-2: (2.92±0.32) pg/ml; IFN-γ: (52.07±3.33) pg/ml](P<0.001). The above experiments also showed similar results when CHO-K1-CD19 cells were used as target cells. Moreover, in a human leukemia xenograft animal model, the results showed that mice in the untransduced T cells group and the control virus transduced T cells group all died within 20 to 30 days, and the hCART19 cell group survived >40 days, which was more than the survival time of the other two groups of mice. The difference was statistically significant (χ(2)=11.73, P=0.008). Conclusion: Humanized CD19 CAR-T cells with anti-leukemic activity have been successfully constructed, which will lay a foundation for clinical studies in the future. 目的: 构建人源化抗CD19嵌合抗原受体T细胞(CAR-T),通过体外实验验证其杀伤白血病细胞的能力。 方法: 将人CD19的鼠源抗体(FMC63)进行了人源化改造,获得高亲和力的人源化CD19抗体;构建携带人源化CD19 CAR慢病毒载体,感染T细胞获得人源化CD19 CAR-T细胞(hCART19);按不同效靶比将效应细胞[hCART19、未转染的T细胞(阴性组)及对照病毒转染的T细胞(对照组)]及靶细胞(CHO-K1-CD19及Raji细胞)混合培养,LDH释放实验及ELISA法检测hCART19杀伤白血病细胞的能力及细胞因子释放水平;白血病小鼠模型检测hCART19的杀瘤效果。 结果: LDH释放实验证实随着效靶比的不断增加,对靶细胞的杀伤率逐渐增加,当效靶比为10∶1时hCART19组的杀伤率最大,在Raji细胞中为(87.56±1.99)%,明显高于阴性组[(19.31±1.16)%]及对照组[(21.35±1.19)%](P值均<0.001)。ELISA法检测显示Raji细胞作为靶细胞时,hCART19组IL-2水平[(10.56±0.88)pg/ml]及IFN-γ[(199.02±12.66)pg/ml]较阴性组[IL-2:(3.55±0.26)pg/ml;IFN-γ:(37.63±0.85)pg/ml]及对照组[IL-2:(2.92±0.32)pg/ml;IFN-γ:(52.07±3.33)pg/ml]明显升高(P值均<0.001)。以上实验在CHO-K1-CD19细胞作为靶细胞时也出现了相似的结果。给予白血病小鼠模型尾静脉分别注射hCART19、对照病毒转染的T细胞及未转染的T细胞,结果显示hCART19组小鼠存活时间>40 d,另外两组小鼠在20~30 d全部死亡,差异有统计学意义(χ(2)=11.73,P=0.008)。 结论: 成功构建了具有抗白血病活性的人源化CD19 CAR-T细胞,为下一步的临床研究奠定了基础。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang CX, Cheng H, Han X, et al. [Construction and in vitro verification of a new humanized anti-CD19 CAR-T cells with high affinity]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30032561. doi:10.3760/cma.j.issn.0253-2727.2018.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。